Search
for
Sort by
Research 781–810 of 1000+
- Sublingual tofacitinib for alopecia areata: a roll‐over pilot clinical trial and analysis of pharmacokinetics
- Topical calcipotriol vs narrowband ultraviolet B in treatment of alopecia areata: a randomized-controlled trial
- Comparative study of efficacy of topical mometasone with calcipotriol versus mometasone alone in the treatment of alopecia areata
- Comparison of efficacy, safety and satisfaction of latanoprost versus minoxidil, betamethasone and in combination in patients with alopecia areata: A blinded multiple group randomized controlled trial
- Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy
- Using qualitative methods to establish the clinically meaningful threshold for treatment success in alopecia areata
- Long-Term Efficacy of Ritlecitinib up to Month 24 From the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata
- Baricitinib for the Treatment of Alopecia Areata
- Wharton’s jelly-derived mesenchymal stem cells in the treatment of four patients with alopecia areata
- Dupilumab for the treatment of alopecia areata in pediatric patients with atopic dermatitis: A scoping review
- Successful treatment of severe atopic dermatitis and alopecia universalis with upadacitinib in a 29-year-old male patient
- Using artificial intelligence to compute Severity of Alopecia Tool scores
- Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
- Study on Serum Vitamin D in Alopecia Areata Patients
- An Excellent Response to Tofacitinib in a Pediatric Alopecia Patient: A Case Report and Review.
- Oral abrocitinib for treatment of refractory alopecia areata: A retrospective study
- European expert consensus statement on the systemic treatment of alopecia areata
- 33766 Efficacy of baricitinib in patients with various degrees of alopecia areata severity: Results from BRAVE-AA1 and BRAVE-AA2
- Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
- FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss
- The evaluation of JAK inhibitors on effect and safety in alopecia areata: a systematic review and meta-analysis of 2018 patients
- Five Cases of Severe Alopecia Areata Treated with Gagamhwajung-hwan
- Safety and Efficacy of Ritlecitinib for the Treatment of Patients with Alopecia Areata: A Systematic Review and Meta-Analysis of Controlled Trials
- 67 Patterns of clinical response in patients with alopecia areata (AA) treated with ritlecitinib in the ALLEGRO phase 2b/3 and ongoing, phase 3, ALLEGRO-LT studies
- Scalp hair regrowth is associated with improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata: results from two randomized controlled trials
- Platelet-rich plasma in the treatment of alopecia areata: A retrospective evaluation of 17 patients
- Evaluation of fractional carbon dioxide laser alone versus its combination with betamethasone valerate in treatment of alopecia areata, a clinical and dermoscopic study
- 34007 Efficacy and safety of baricitinib in adult patients with severe alopecia areata with or without an atopic background from 2 randomized, placebo-controlled, phase 3 trials
- LB785 Efficacy and safety of baricitinib in adults with Alopecia Areata: Phase 3 results from a randomized controlled trial (BRAVE-AA1)
- Alopecia Areata: A Complex Cytokine Driven Disease